Insmed (INSM) reported preliminary 2024 revenue results for its drug Arikayce and issued 2025 revenue guidance. Read more ...

SkyWest's strong fundamentals include predictable revenues from capacity purchase agreements, consistent debt reduction, and ...

US job growth surged in December, surpassing expectations. The services sector drove gains, but wage growth slightly slowed.

NuScale's regulatory approval for SMRs in the U.S. gives it a unique market position, with a major project to go live in 2029 ...

Is IBM's software business growth underestimated due to AI expansion? Its P/E ratio has increased significantly, impacting ...

“We see more good than bad happening in 2025 and believe this will cause Softline’s’ valuation gap vs the S&P 500 to narrow, ...

Starbucks' premium valuation is harder to justify amid declining performance. Find out why SBUX stock may face more downside, ...

The Hershey Company is a strong hold, but Mondelez offers growth potential. See why HSY and MDLZ stocks could offer better ...

Sanofi’s Dupixent and new drugs drive growth, despite near-term pressures. See why SFY stock’s product pipeline makes it a ...

Washington Trust Bancorp has seen significant growth, but now faces mixed financial performance. Click here to find out why I ...

Microsoft’s focus on long-term AI success explains recent stock behavior. See why MSFT stock, with recent reallocations, is ...

BioCryst ( NASDAQ: BCRX) released its preliminary 2024 revenue results, along with guidance for 2025. The company said it ...